Atopic Dermatitis News and Research

RSS

Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.

HSV-1 exploits immune system receptor to boost infectivity and cause disease

Researchers at the University of California, San Diego School of Medicine and colleagues report that the herpes simplex virus type-1 (HSV-1), which affects an estimated 50 to 80 percent of all American adults, exploits an immune system receptor to boost its infectivity and ability to cause disease.

7 Jun 2013

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Atopix Therapeutics Ltd, a biopharmaceutical company developing a novel class of anti-allergic medicines, has been awarded a £1.7 million grant from the UK Biomedical Catalyst fund to pursue development of OC459 in the treatment of moderate-to-severe atopic dermatitis (a form of eczema).

29 May 2013

Patient compliance: an interview with Dr. Bassam Damaj, CEO of Innovus Pharma

A medication’s optimal results are achieved with specific dose levels and times of administration. In order for patients to achieve the maximum benefit from a medication, they have to adhere to the prescribed dose and time of use.

20 May 2013

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled their first patients.

15 May 2013

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients.

10 May 2013

Regeneron Pharmaceuticals expands ophthalmology portfolio

Regeneron Pharmaceuticals, Inc. today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi.

3 May 2013

Experts and patients share tips on preventing skin cancer

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers.

26 Apr 2013

Data on PV-10 combination therapy presented at AACR Annual Meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research Annual Meeting in Washington, DC.

11 Apr 2013

Anacor signs research agreement to discover drug candidates to treat neglected diseases

Anacor Pharmaceuticals today announced that it has signed a research agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to discover drug candidates intended to treat two filarial worm diseases (onchocerciasis, or river blindness, and lymphatic filariasis, commonly known as elephantiasis) and tuberculosis.

9 Apr 2013

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.

25 Mar 2013

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

4 Mar 2013

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Anacor Pharmaceuticals today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302).

28 Feb 2013

Mental health risk increased in children with atopic dermatitis

Results from a US study suggest that children with atopic dermatitis (AD) are at significantly increased risk for mental health disorders.

25 Feb 2013

Regeneron fourth quarter total revenues increase to $415 million

Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the fourth quarter and full year 2012 and provided an update on development programs.

14 Feb 2013

Innate lymphoid cells may be new therapeutic target in treating atopic dermatitis

The increasing incidence of allergic skin diseases, and the accompanying economic burden and heightened risk of developing other allergic conditions, have spurred researchers to look for better ways to control these immune system-based disorders.

1 Feb 2013

New insight into eczema’s itch

Research shows that innate lymphoid cells accumulate in active eczema lesions and may contribute to disease progression.

31 Jan 2013

Asthma linked to atopic dermatitis persistence

Asthma is associated with rash persistence in children with atopic dermatitis, US researchers report.

28 Jan 2013

Data from Provectus' PV-10 pre-clinical study on melanoma to be presented at AACR meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data on PV-10 will be presented in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC.

23 Jan 2013

Itch-specific nerve cells: an interview with Associate Professor Xinzhong Dong

Itch was actually defined by a German physician more than 350 years ago. His name was Samuel Hafenreffer. He defined itch as an unpleasant sensation that makes people want to scratch. You probably think this is a very simple definition but itch is really a very complex sensory modality.

21 Jan 2013

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

9 Jan 2013